CAPTRUST Financial Advisors
CBAY

CAPTRUST Financial Advisors’s Cymabay Therapeutics CBAY Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,973
Closed -$732K – 2730
2023
Q4 		$732K Sell
30,973
-14,536
-32% -$259K ﹤0.01% 1473
2023
Q3 		$679K Buy
+45,509
New +$603K ﹤0.01% 1438
2022
Q3 		– Sell
-5,628
Closed -$17K – 4324
2022
Q2 		$17K Sell
5,628
-1,628
-22% -$3.89K ﹤0.01% 3469
2022
Q1 		$23K Hold
7,256
– – ﹤0.01% 3312
2021
Q4 		$25K Buy
7,256
+1,241
+21% +$4.71K ﹤0.01% 3153
2021
Q3 		$22K Hold
6,015
– – ﹤0.01% 3103
2021
Q2 		$26K Hold
6,015
– – ﹤0.01% 2946
2021
Q1 		$27K Buy
6,015
+2,515
+72% +$13.5K ﹤0.01% 2824
2020
Q4 		$20K Hold
3,500
– – ﹤0.01% 2260
2020
Q3 		$25K Buy
+3,500
New +$18.7K ﹤0.01% 1887

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CAPTRUST Financial Advisors's CBAY Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 30,973 shares — an estimated $732K sold.

CAPTRUST Financial Advisors first reported a position in CBAY in Q3 2020 and held it in 10 quarters. The position peaked at $732K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 30,973 Cymabay Therapeutics shares in Q1 2024, an estimated $732K.
  • CAPTRUST Financial Advisors first reported a position in Cymabay Therapeutics in Q3 2020 and held it in 10 quarters.
  • CAPTRUST Financial Advisors's Cymabay Therapeutics position peaked at $732K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.